(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
At least 11 killed in South Africa mass shooting - 2Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- 3Single women risk rape and exploitation in search for better life in Europe
- 4Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
- 5Outer space conditions hamper sperm's ability to navigate toward an egg
- Ways to track down the Right Criminal Legal counselor
- Vote In favor of Your Favored Cereal
- Spots To Go Birdwatching All over the Planet
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- How to watch the 2025 Macy's Thanksgiving Day Parade for free
- Cocoa Prices Sink on Favorable Crop Conditions in West Africa
- Hot Electric Vehicles for 2023
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Energy agency chief warns of 'black April' for oil supplies
